Demand for humanitarian assistance is growing and existing financial resources are inadequate to address all areas of need. As stewards of limited funds, we have a responsibility to make the most ...
As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...
This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis. Objectives: To estimate the ...
CAR-T therapy's cost per QALY is approximately $100,000, with consistent results across PSM, STM, and DES models. DES uniquely incorporates wait time, significantly affecting CAR-T's ...
To address the gap between opportunity costs and cost-effectiveness thresholds, we must identify the marginal cost of a unit of health for health care systems. Amid efforts to reduce spending on ...
The inclusion of dynamic drug pricing in cost-effectiveness analysis is important for value assessments of new drugs. The drug price-related provisions of the Inflation Reduction Act make the case for ...
Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102 A randomized controlled trial ...
Patterns of Complementary Medicine Utilization in Patients With Breast Cancer and Colorectal Cancer: A Cross-Sectional Study at a Tertiary Referral Hospital in Yogyakarta, Indonesia A partitioned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results